Trial of sulfasalazine in patients with sickle cell disease.

Data are shown as the percent of positive CECs for VCAM-1 (open squares), ICAM-1 (open triangles), E-selectin (open circles), and tissue factor (heavy solid line). Time scale is in days, with each mark indicating a 2-day interval. Drug administrations are indicated at the bottom of the graphs by bars (solid bar indicates sulfasalazine and open bar, salsalate), and the starting and ending days of the individual exposure trials are indicated on the horizontal axis. Patient A was given sulfasalazine 3 separate times (once with salsalate added) and was once given salsalate alone. Patient B was given sulfasalazine alone 2 separate times. The second drug exposure period was interrupted for 3 days when no drugs were taken. Patient C was given sulfasalazine 2 times (once with salsalate added).